A New Viral Coinfection: SARS-CoV-2 Pneumonia and Cytomegalovirus Pneumonitis in a Renal Transplant Recipient
Abstract
:1. Introduction
2. Case Description
3. Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
Appendix A
Variable | Reference Range | OSH Admission † | Day 1 ‡ | Day 4 | Day 8 | Day 12 § | Day 23 |
---|---|---|---|---|---|---|---|
COVID-19 | Negative | Positive (PCR) | Positive (Rapid ID NOW) | - | - | - | - |
Lactic Acid | 0–2.2 mMol/L | 0.70 | 0.85 | - | - | - | - |
C Reactive Protein | <0.8 mg/dL | - | 18.0 (H) | - | - | 19.2 (H) | - |
Procalcitonin | <0.07 ng/mL | 0.25 (H) | 0.4 (H) | - | - | - | - |
D-Dimer | <0.5 μg/mL | - | 0.83 (H) | - | 9.46 (H) | - | 1.29 (H) |
Creatinine | 0.6–1.25 g/dL | - | 1.32 (H) | 2.59 (H) | 2.35 (H) | 0.99 | 0.85 |
Albumin | 3.5–5.0 g/dL | - | 2.4 (L) | 2.6 (L) | - | - | - |
Lactate Dehydrogenase | 300–600 U/L | - | 1050 (H) | 1327 (H) | - | - | - |
White Blood Cell Count | 4.2–10.7 × 103/μL | - | 6.07 | 5.12 | - | 0.99 (L) | 5.6 |
Absolute Neutrophil Count | 1.99–6.95 × 103/μL | - | 5.71 | 4.92 | - | 0.57 (L) | 4.78 |
Absolute Lymphocyte Count | 1.09–3.23 × 103/μL | - | 0.22 (L) | 0.11 (L) | - | 0.11 (L) | 0.54 (L) |
Oxygen Requirement | - | High-Flow (30 L/min, 100% FiO2) | Non-Rebreather Mask (15 L/min) | High-Flow (50 L/min, 100% FiO2) | High-Flow (55 L/min, 60% FiO2) | High-Flow (55 L/min, 70% FiO2) | Nasal Cannula (4 L) |
Lab | Reference Range | Renal Transplant † | CV 1 ‡ | CV 2 ‡ | Day 2 § | Day 10 | Day 18 | Day 24 | Day 32 ¶ |
---|---|---|---|---|---|---|---|---|---|
CMV IgG | Negative | Negative | - | - | - | - | - | - | - |
CMV PCR | <2.5 log IU/mL | - | 4.6 | 3.2 | 4.3 | 4.7 | 3.9 | 2.9 | 2.7 |
CMV PCR (log) | <300 IU/mL | - | 36,814 | 1644 | 21,130 | 55,098 | 7293 | 735 | 461 |
CMV PCR | <2.7 log copies/mL | - | 4.8 | 3.5 | 4.6 | 5.0 | 4.1 | 3.1 | 2.9 |
CMV PCR (log) | <516 copies/mL | - | 63,320 | 2828 | 36,344 | 94,769 | 12,544 | 1264 | 793 |
Lab | OSH † | UTMB |
---|---|---|
Urinalysis | Negative | Negative |
Coccidiodes Ab IgM | Negative | Negative |
Coccidiodes Ab IgG | Negative | Negative |
Cryptococcal Antigen | Negative | Negative |
Histoplasma Antigen | - | Negative |
Histoplasma Antigen (Urine) | Negative | Negative |
Fungitell | Negative | Negative |
Blood Culture | - | No Growth |
Urine Culture | - | No Growth |
Fungal Culture | - | No Growth |
AFB Culture | - | No Growth |
Respiratory Viral Panel | - | Negative |
Pneumococcal Antigen (Urine) | - | Negative |
Legionella Antigen (Urine) | - | Negative |
Aspergillus Galactomannan Antigen | - | Negative |
References
- World Health Organization. Coronavirus Disease (COVID-19) Weekly Epidemiological Update. Available online: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200831-weekly-epi-update-3.pdf?sfvrsn=d7032a2a_4 (accessed on 26 August 2020).
- Li, X.; Xu, S.; Yu, M.; Wang, K.; Tao, Y.; Zhou, Y.; Shi, J.; Zhou, M.; Wu, B.; Yang, Z.; et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J. Allergy Clin. Immunol. 2020, 146, 110–118. [Google Scholar] [CrossRef]
- Karuthu, S.; Blumberg, E.A. Common infections in kidney transplant recipients. Clin. J. Am. Soc. Nephrol. 2012, 7, 2058–2070. [Google Scholar] [CrossRef] [Green Version]
- Humar, A.; Gregson, D.; Caliendo, A.M.; McGeer, A.; Malkan, G.; Krajden, M.; Corey, P.; Greig, P.; Walmsley, S.; Levy, G.; et al. Clinical utility of quantitative cytomegalovirus viral load determination for predicting cytomegalovirus disease in liver transplant recipients. Transplantation 1999, 68, 1305–1311. [Google Scholar] [CrossRef] [Green Version]
- Cariani, E.; Pollara, C.P.; Valloncini, B.; Perandin, F.; Bonfanti, C.; Manca, N. Relationship between pp65 antigenemia levels and real-time quantitative DNA PCR for Human Cytomegalovirus (HCMV) management in immunocompromised patients. BMC Infect. Dis. 2007, 7, 138. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Humar, A.; Michaels, M.; AST ID Working Group on Infectious Disease Monitoring. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am. J. Transplant. 2006, 6, 262–274. [Google Scholar] [CrossRef] [PubMed]
- Hartmann, A.; Sagedal, S.; Hjelmesaeth, J. The natural course of cytomegalovirus infection and disease in renal transplant recipients. Transplantation 2006, 82 (Suppl. 2), S15–S17. [Google Scholar] [CrossRef] [PubMed]
- Lurain, N.S.; Chou, S. Antiviral drug resistance of human cytomegalovirus. Clin. Microbiol. Rev. 2010, 23, 689–712. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Avery, R.K. Low-dose valganciclovir for cytomegalovirus prophylaxis in organ transplantation: Is less really more? Clin. Infect. Dis. 2011, 52, 322–324. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Halim, M.A.; Al-Otaibi, T.; Gheith, O.; Adel, H.; Mosaad, A.; Hasaneen, A.-A.; Zakaria, Z.; Makkeya, Y.; Said, T.; Nair, P. Efficacy and Safety of Low-Dose Versus Standard-Dose Valganciclovir for Prevention of Cytomegalovirus Disease in Intermediate-Risk Kidney Transplant Recipients. Exp. Clin. Transplant. 2016, 14, 526–534. [Google Scholar] [CrossRef] [PubMed]
- Stevens, D.R.; Sawinski, D.; Blumberg, E.; Galanakis, N.; Bloom, R.D.; Trofe-Clark, J. Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis. Transpl. Infect. Dis. 2015, 17, 163–173. [Google Scholar] [CrossRef] [PubMed]
- Dupuis, R.; Harris, M.; Gillis, K.; Gerber, D.; Fair, J.; Watson, R.; Koslowski, T.; Andreoni, K. Experience with low-dose valganciclovir prophylaxis in adult liver transplant recipients. Transplant. Proc. 2007, 39, 3266–3270. [Google Scholar] [CrossRef] [PubMed]
- Boeckh, M.; Geballe, A.P. Cytomegalovirus: Pathogen, paradigm, and puzzle. J. Clin. Investig. 2011, 121, 1673–1680. [Google Scholar] [CrossRef] [PubMed]
- Hantz, S.; Garnier-Geoffroy, F.; Mazeron, M.-C.; Garrigue, I.; Merville, P.; Mengelle, C.; Rostaing, L.; Marcoux, F.S.; Essig, M.; Rerolle, J.-P.; et al. Drug-resistant cytomegalovirus in transplant recipients: A French cohort study. J. Antimicrob. Chemother. 2010, 65, 2628–2640. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chou, S.; Ercolani, R.J.; Vanarsdall, A.L. Differentiated Levels of Ganciclovir Resistance Conferred by Mutations at Codons 591 to 603 of the Cytomegalovirus UL97 Kinase Gene. J. Clin. Microbiol. 2017, 55, 2098–2104. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Razonable, R.R.; Humar, A. Cytomegalovirus in solid organ transplant recipients-Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice. Clin. Transplant. 2019, 33, e13512. [Google Scholar] [CrossRef] [PubMed]
- Molyvdas, A.; Matalon, S. Cyclosporine: An old weapon in the fight against Coronaviruses. Eur. Respir. J. 2020, 2002484. [Google Scholar] [CrossRef] [PubMed]
- Chen, D.; Yang, B.; Zhang, Y.; Chen, L.; Wei, L.; Zhang, W.; Wang, X.; Tong, L.; Chen, Z. Withdrawing mycophenolate mofetil in treating a young kidney transplant recipient with COVID-19: A case report. Medicine 2020, 99, e20481. [Google Scholar] [CrossRef] [PubMed]
- Bataille, S.; Moal, V.; Gaudart, J.; Indreies, M.; Purgus, R.; Dussol, B.; Zandotti, C.; Berland, Y.; Vacher-Coponat, H. Cytomegalovirus risk factors in renal transplantation with modern immunosuppression. Transpl. Infect. Dis. 2010, 12, 480–488. [Google Scholar] [CrossRef] [PubMed]
- Arpali, E.; Akyollu, B.; Yelken, B.; Tekin, S.; Turkmen, A.; Kocak, B. Case report: A kidney transplant patient with mild COVID-19. Transpl. Infect. Dis. 2020, 22, e13296. [Google Scholar] [CrossRef] [PubMed]
- D’Ardes, D.; Boccatonda, A.; Schiavone, C.; Santilli, F.; Guagnano, M.T.; Bucci, M.; Cipollone, F. A Case of Coinfection with SARS-COV-2 and Cytomegalovirus in the Era of COVID-19. Eur. J. Case Rep. Intern. Med. 2020, 7, 001652. [Google Scholar] [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Shaikh, A.S.; Shaim, H.; Caravedo, M.A.; Ong, K.M.; Reynoso, D. A New Viral Coinfection: SARS-CoV-2 Pneumonia and Cytomegalovirus Pneumonitis in a Renal Transplant Recipient. COVID 2021, 1, 115-119. https://0-doi-org.brum.beds.ac.uk/10.3390/covid1010010
Shaikh AS, Shaim H, Caravedo MA, Ong KM, Reynoso D. A New Viral Coinfection: SARS-CoV-2 Pneumonia and Cytomegalovirus Pneumonitis in a Renal Transplant Recipient. COVID. 2021; 1(1):115-119. https://0-doi-org.brum.beds.ac.uk/10.3390/covid1010010
Chicago/Turabian StyleShaikh, Abdullah S., Hila Shaim, Maria A. Caravedo, Karen M. Ong, and David Reynoso. 2021. "A New Viral Coinfection: SARS-CoV-2 Pneumonia and Cytomegalovirus Pneumonitis in a Renal Transplant Recipient" COVID 1, no. 1: 115-119. https://0-doi-org.brum.beds.ac.uk/10.3390/covid1010010